RJA
ABBV icon

Raymond James & Associates’s AbbVie ABBV Stock Holding History

Raymond James & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37,900
Closed -$86.5K – 3871
2022
Q4 		$86.5K Buy
37,900
+9,100
+32% +$1.4M ﹤0.01% 3664
2022
Q3 		$7K Sell
28,800
-8,900
-24% -$1.28M ﹤0.01% 3873
2022
Q2 		$265K Sell
37,700
-11,200
-23% -$1.71M ﹤0.01% 3309
2022
Q1 		$431K Sell
48,900
-11,700
-19% -$1.7M ﹤0.01% 3152
2021
Q4 		$560K Sell
60,600
-6,300
-9% -$744K ﹤0.01% 3001
2021
Q3 		$51K Buy
66,900
+18,300
+38% +$2.09M ﹤0.01% 3913
2021
Q2 		$37K Buy
48,600
+38,400
+376% +$4.32M ﹤0.01% 3942
2021
Q1 		$3K Sell
10,200
-47,500
-82% -$5.08M ﹤0.01% 3973
2020
Q4 		$285K Buy
57,700
+26,400
+84% +$2.54M ﹤0.01% 3151
2020
Q3 		$36K Sell
31,300
-2,500
-7% -$235K ﹤0.01% 3468
2020
Q2 		$50K Buy
33,800
+1,100
+3% +$96.8K ﹤0.01% 3376
2020
Q1 		$8K Buy
32,700
+20,300
+164% +$1.73M ﹤0.01% 3451
2019
Q4 		$26K Sell
12,400
-900
-7% -$74.7K ﹤0.01% 3599
2019
Q3 		$36K Sell
13,300
-100
-0.7% -$6.86K ﹤0.01% 3499
2019
Q2 		$2K Sell
13,400
-71,200
-84% -$5.6M ﹤0.01% 3621
2019
Q1 		$12K Buy
84,600
+14,800
+21% +$1.21M ﹤0.01% 3559
2018
Q4 		$87K Sell
69,800
-41,200
-37% -$3.62M ﹤0.01% 3322
2018
Q3 		$39K Sell
111,000
-27,200
-20% -$2.58M ﹤0.01% 3505
2018
Q2 		$44K Buy
138,200
+15,300
+12% +$1.49M ﹤0.01% 3446
2018
Q1 		$231K Sell
122,900
-33,700
-22% -$3.7M ﹤0.01% 3056
2017
Q4 		$452K Sell
156,600
-44,800
-22% -$4.22M ﹤0.01% 2592
2017
Q3 		$1.59M Buy
201,400
+56,800
+39% +$4.32M ﹤0.01% 1799
2017
Q2 		$307K Buy
144,600
+11,100
+8% +$746K ﹤0.01% 2705
2017
Q1 		$43K Buy
133,500
+27,900
+26% +$1.75M ﹤0.01% 3153
2016
Q4 		$63K Buy
105,600
+84,100
+391% +$5.13M ﹤0.01% 3073
2016
Q3 		$9K Buy
21,500
+1,400
+7% +$90.6K ﹤0.01% 3171
2016
Q2 		$27K Sell
20,100
-1,200
-6% -$73.1K ﹤0.01% 2919
2016
Q1 		$9K Buy
+21,300
New +$1.19M ﹤0.01% 2890

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's ABBV Position: Q3 2024 in Review

Raymond James & Associates increased its AbbVie (ABBV) stake by 0.6% in Q3 2024, buying an estimated $5.03M and bringing the position to 4,533,099 shares worth $895M. The position accounts for 0.55% of the portfolio, ranked #29.

Raymond James & Associates first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • Raymond James & Associates held 4,533,099 shares of AbbVie worth $895M as of Q3 2024.
  • Raymond James & Associates bought 26,954 AbbVie shares in Q3 2024, an estimated $5.03M.
  • AbbVie made up 0.55% of Raymond James & Associates's portfolio in Q3 2024, its #29 holding.
  • Raymond James & Associates first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
  • 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.